MONOVALENT ANTI-MERTK ANTIBODIES AND METHODS OF USE THEREOF

ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE

CHIMERIC POLYPEPTIDE ASSEMBLY AND METHODS OF MAKING AND USING THE SAME

MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE SAME AND USES THEREOF

METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER

TARGETED ADAM17 BLOCKER COMPOUNDS, ANTI-ADAM17 ANTIBODIES, METHODS OF MAKING, AND METHODS OF USING

CX3CR1-BINDING POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS

USE OF MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR IN THE TREATMENT OF PATIENTS WITH HYPOXEMIC ACUTE RESPIRATORY FAILURE

Anti-CD161 antibodies and uses thereof

MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE

COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY

BISPECIFIC ANTI-MERTK AND ANTI-PDL1 ANTIBODIES AND METHODS OF USE THEREOF

CELLS EXPRESSING VISTA ANTIGEN-BINDING MOLECULES

METHOD OF TREATING CANCER BY ADMINISTRATION OF AN ANTI-PD-1 OR ANTI-PD-L1 THERAPEUTIC AGENT VIA A LYMPHATIC MICRONEEDLE DELIVERY DEVICE

ANTI-CD276 MAB TO TARGET BREAST CANCER

CD28 SHEDDING BLOCKING AGENTS

Anti-CD3 constructs and uses thereof

ERYTHROCYTE-BINDING THERAPEUTICS

METHODS OF USE OF ANTI-IL-2 ANTIBODIES

METHODS TO GLYCOENGINEER PROTEINS

DUAL SPECIFIC ANTIBODIES

ANTIGEN-BINDING MOLECULE PROMOTING DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES

ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE

ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE

DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING DERMATOMYOSITIS (DM)

UNGULATE-DERIVED POLYCLONAL IMMUNOGLOBULIN SPECIFIC FOR INFLUENZA VIRUS AND USES THEREOF

Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods

A PHAGE-DISPLAYED SINGLE-CHAIN VARIABLE FRAGMENT LIBRARY FOR SELECTING ANTIBODY FRAGMENTS SPECIFIC TO MESOTHELIN

COMPOSITIONS

ANTIBODY-NKG2D LIGAND DOMAIN FUSION PROTEIN

HIGH CONCENTRATION FORMULATION AND USES THEREOF

COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR

COMPOSITIONS AND METHODS FOR DETERMINING RESPONSIVENESS TO IMMUNE CHECKPOINT INHIBITORS (ICI), INCREASING EFFECTIVENESS OF ICI, AND TREATING CANCER

RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

IMMUNO-ONCOLOGY THERAPEUTIC COMPOSITION USING ADJUVANT INCLUDING LIPOPEPTIDES AND POLY (I:C)

Suppressive T Cell Populations and Methods of Cancer Immunotherapy

Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus

PHARMACEUTICAL KITS AND USES THEREOF FOR TREATING COLORECTAL CANCER

COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS

METHODS AND COMPOSITIONS FOR MODULATING STING SIGNALING AND INNATE IMMUNE RESPONSES

GENETICALLY-MODIFIED SACCHAROMYCES YEAST STRAINS AS PREVENTATIVE AND THERAPEUTIC AGENTS

ANTI-KLB ANTIBODIES AND USES

DOSING FOR ANTI-TRYPTASE ANTIBODIES

ANTIBODY OR FRAGMENT THEREOF, AND METHOD FOR USING SAME

Anti-CUB domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof

Anti-SIRP-Alpha Antibodies and Methods of Use Thereof

COMPOSITIONS AND METHODS FOR INJECTING PARTICLE SUSPENSIONS

ANTI-CD20 ANTIBODY COMPOSITIONS

USE OF B CELL DEPLETING AGENTS FOR THE TREATMENT OF RHEUMATIC HEART DISEASE

THERAPEUTICS AND METHODS FOR TREATING OR AMELIORATING METABOLIC DISORDERS

ANTI-IL-36R ANTIBODY AND USE THEREOF

CANCER METASTASIS INHIBITOR

ENGINEERED BMP2 SURROGATE PROTEINS

ANTI-DDR2 ANTIBODIES AND USES THEREOF

ENGINEERED ANTIBODY FC VARIANTS FOR ENHANCED SERUM HALF LIFE

METHODS OF TREATING CANCER WITH BISPECIFIC EGFR XCD28 ANTIBODIES ALONE OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES

TREM2 AGONIST BIOMARKERS AND METHODS OF USE THEREOF

ANTI-LILRB1 ANTIBODY AND USES THEREOF

ANTIBODIES AGAINST CD112R AND USES THEREOF

IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF

BINDING AGENTS

Acute treatment and rapid treatment of headache using anti-CGRP antibodies

METHODS FOR TREATING ALZHEIMER'S DISEASE

HUMAN NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 SPIKE S2 DOMAIN AND USES THEREOF

ANTIBODIES THAT BIND SARS-COV-2 SPIKE PROTEIN

RECOMBINANT PROTEIN HAVING FUSED INTERFERON-BETA MUTEIN AND ANTIBODY, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

PROTEASE-ACTIVATED CYTOKINE

DRUG CONJUGATE AND USE THEREOF

THERAPEUTIC TARGETING OF CADHERIN 11 IN CANCER

PHARMACEUTICAL FORMULATION CONTAINING AN ANTI-IgE ANTIBODY

ANTI-CD47 ANTIBODY FOR COMBINED TREATMENT OF BLOOD TUMOR

TREATMENT FOR BONE DISEASES

Pharmaceutical Composition for Treatment of Mucopolysaccharidosis Type 1

HETERODIMERIC FC DOMAIN ANTIBODIES

STABLE LIQUID PHARMACEUTICAL PREPARATION

STABLE LIQUID PHARMACEUTICAL PREPARATION

SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS

CYTOTOXICITY-INDUCING THERAPEUTIC AGENT

Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof

ANTI-MUC16 ANTIBODIES

Fusion Protein Containing BDNF

COMBINATION DOSAGE REGIME OF CD137 AND PD-L1 BINDING AGENTS

PROTEINS THAT BIND CD80 AND/OR CD86, AND OX40L

GPRC5D CHIMERIC ANTIGEN RECEPTORS AND CELLS EXPRESSING THE SAME

DOSING REGIMENS FOR PROTEIN THERAPEUTICS

FC-MODIFIED WNT SURROGATE MOLECULES AND USES THEREOF

ANTIBODIES AGAINST ALK AND METHODS OF USE THEREOF

ANTI-TIGIT ANTIBODY AND DOUBLE ANTIBODY AND THEIR APPLICATION

MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOF

PROMISCUOUS CD3 BINDING MOLECULES

ANTI-CD33 ANTIBODIES AND USES THEREOF

TIM-3 MODULATES ANTI-TUMOR IMMUNITY BY REGULATING INFLAMMASOME ACTIVATION

ANTI-IGSF1 ANTIBODY AND USE THEREOF

METHODS FOR TREATING HYPERTENSION USING AN ANTI-BMP10 MONOCLONAL ANTIBODY OR FRAGMENT THEREOF

COMPOUNDS AND METHODS FOR TREATING PAIN

Composition and method for the diagnosis and treatment of iron-related disorders

ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS AND USE THEREOF

BINDING POLYPEPTIDES AGAINST SARS COV-2 AND USES THEREOF

NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2

TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR

FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES

LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME

METHODS FOR REDUCING OR ELIMINATING THE NEED FOR LIPOPROTEIN APHERESIS IN PATIENTS WITH HYPERLIPIDEMIA BY ADMINISTERING ALIROCUMAB

METHODS OF TREATING LUNG CANCER WITH A PD-1 AXIS BINDING ANTAGONIST, A PLATINUM AGENT, AND A TOPOISOMERASE II INHIBITOR

Bispecific or-gate chimeric antigen receptor responsive to CD20 and CD19

COMBINATIONS OF WEE1 INHIBITORS AND ANTI-CD47 ANTIBODIES

COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER

DPEP-1 BINDING AGENTS AND METHODS OF USE

ANTI-ALK ANTIBODIES AND USES THEREOF

Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders

Human Anti-SOD1 Antibodies

ANTI-uPAR ANTIBODIES AND USES THEREOF

TROGOCYTOSIS-MEDIATED THERAPY USING CD38 ANTIBODIES

Anti-CD45 antibodies and conjugates thereof

Anti-BAFF Antibodies for use in a Method of Treatment of Long Covid and/or Post-Acute Sequelae SARS-CoV-2 Infection (PASC)

ANTI-CD30L ANTIBODIES AND USES THEREOF

ANTIGEN BINDING MOLECULE SPECIFICALLY BINDING TO RANKL AND NGF, AND MEDICAL USE THEREOF

GFRAL-ANTAGONISTIC ANTIBODY HAVING IMPROVED AFFINITY, AND USE THEREOF

DEPLETION OF ACTIVATED HEPATIC STELLATE CELLS (HSCS) AND USES THEREOF

COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER

PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION

BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO CD47 AND PD-L1

TRISPECIFIC ANTIBODY AND PREPARATION METHOD THEREFOR AND USE THEREOF

THERAPEUTIC ANTIBODIES

Anti-CD300LB Antibodies and Methods of Use Thereof

ANTI-TREM-1 ANTIBODIES

ANTIBODIES

Anti-sema3a antibodies and uses thereof

Anti-CEACAM6 antibodies and methods of use

COMBINED THERAPY USING ANTI-CD300C ANTIBODY

NOVEL WNT AGONIST ANTIBODIES AND THERAPEUTIC USES THEREOF

COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES BY INHIBITING FSH

VARIANT LIBRARY-COUPLED IMMUNOGENICITY MAPPING OF MONOCLONAL ANTIBODY THERAPEUTICS

Antibody capable of binding to thymic stromal lymphopoietin and use thereof

TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF Fab

GDF15 MODULATOR FOR USE IN INHIBITION OF OCULAR TISSUE FIBROSIS

PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE

BRAIN TARGETING COMPOSITIONS AND METHODS OF USE THEREOF

GENERATION OF HUMAN PEANUT ALLERGEN-SPECIFIC IGE MONOCLONAL ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE

COMPOSITIONS AND METHODS FOR USING BISPECIFIC ANTIBODIES TO BIND COMPLEMENT AND A TARGET ANTIGEN

MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF

Human Immunodeficiency Virus Neutralizing Antibodies And Methods Of Use Thereof

ANTI-INFLUENZA NEURAMINIDASE MONOCLONAL ANTIBODIES AND USES THEREOF

MONOCLONAL ANTIBODY 2G1 FOR BROAD-SPECTRUM NEUTRALIZATION OF EBOLA VIRUSES AND APPLICATION THEREOF

HUMAN ANTIBODY SPECIFICALLY BINDING TO BINDING SITE OF HEPATOCYTE RECEPTOR OF HEPATITIS B VIRUS PRES1 ANTIGEN, AND USE THEREOF

CD33 SPECIFIC CHIMERIC ANTIGEN RECEPTORS

IL-15 FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME

COMPLEMENT FACTOR H AND Fc BINDING DOMAIN FUSION PROTEINS

ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER

METHODS AND COMPOSITIONS FOR INCREASING THE ACTIVITY IN THE CNS OF HEXOSAMINIDASE A, ACID SPHINGOMYELINASE, AND PALMITOYL-PROTEIN THIOESTERASE 1

PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD37 ANTIBODIES

Injectable Polymeric Biopharmaceutical Formulations

TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTORS

METHODS AND COMPOSITIONS COMPRISING A CARDIO-TOLERATED HDAC INHIBITOR

BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS

HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS OF TREATING SUBJECTS SUFFERING FROM ATYPICAL HEMOLYTIC SYNDROME

CYP1A1-TARGETED MONOCLONAL ANTIBODY WITH REACTIVITY ACROSS VERTEBRATE TAXA

COAGULATION FACTOR XI (FXI) BINDING PROTEIN

DEVELOPMENT AND USE OF FUNCTION-ENHANCED ANTIBODY BLOCKING AGENT

COMPOSITIONS AND METHODS FOR T-CELL AND CYTOKINE ACTIVATION

FGFR3 BINDING MOLECULES AND METHODS OF USE THEREOF

METHODS OF TREATMENT OF CANCER PATIENTS HAVING ALTERED SETD2 BIOMARKER WITH A PD-1 ANTAGONIST

METHODS OF TREATING CANCER PAIN BY ADMINISTERING A PD-1 INHIBITOR

Methods and Compositions for Modulating Beta Chain Mediated Immunity

GROUP B ADENOVIRUS ENCODING AN ANTI-TCR-COMPLEX ANTIBODY OR FRAGMENT

HUMANIZED ANTIBODIES TO LIV-1 AND USE OF SAME TO TREAT CANCER

CELL-PENETRATING ANTI-DNA ANTIBODIES AND USES THEREOF INHIBIT DNA REPAIR

Anti-amyloid beta protofibril/oligomer antibodies and uses thereof

ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS

METHODS OF IMMUNOTHERAPY

VASOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTOR ANTAGONISTS

Interleukin-2 agents and uses thereof

TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO ANTI-MATRIPTASE ANTIBODIES BY IN VIVO CLEAVABLE LINKING MOIETIES

FRACTIONATED RADIOTHERAPY AND CHEMOTHERAPY WITH AN OXYGEN THERAPEUTIC

PYRIMIDINE COMPOUND

METHODS FOR INHIBITING DIAZEPAM BINDING PROTEIN

Atomic description of immune complex that causes heparin-induced thrombocytopenia

BICYCLE CONJUGATES SPECIFIC FOR NECTIN-4 AND USES THEREOF

MULTISPECIFIC ANTIBODIES BINDING TO TUMOR-ASSOCIATED ANTIGENS CAUSING NO OR REDUCED NERVE PAIN IN THE TREATMENT OF CANCER

COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS USING A CD14 INHIBITOR

TREATMENT FOR LUPUS NEPHRITIS USING ANTI-BAFFR ANTIBODIES

Antagonistic CD40 Monoclonal Antibodies and Uses Thereof

MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE OR CYSTEINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF

CO-STIMULATORY MULTISPECIFIC ANTIBODIES

TCR MIMIC MONOCLONAL ANTIBODIES REACTIVE WITH THE PHOSPHO-NEOANTIGEN PIRS2/HLA-A*02:01 COMPLEX AND USES THEREOF

COMBINATION THERAPY WITH A RAF INHIBITOR AND A PD-1 AXIS INHIBITOR

ANTI-PD-1 POLYPEPTIDES AND THEIR USE

ANTI-CD3-FOLATE CONJUGATES AND THEIR USES

ANTI-TIGIT ANTIBODIES AND THEIR USE

ANTIBODIES FOR TREATING CANCER

SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES

MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15)

Treatment of headache using anti-CGRP antibodies

Fc VARIANTS WITH ALTERED BINDING TO FcRn

BINDING MOLECULE AGAINST DLL3 AND USE THEREOF

ANTIGEN BINDING POLYPEPTIDES

NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

METHODS OF TREATING AN EYE DISORDER

Hypoimmunogenic Biotherapeutics

USE OF IMMUNE CHECKPOINT INHIBITORS IN CENTRAL NERVOUS SYSTEMS NEOPLASMS

CANCER IMMUNOTHERAPY BY DELIVERY OF mRNA

TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR

METHODS OF TUMOUR THERAPY WITH A COMBINATION MEDICAMENT COMPRISING IL-12 AND AN AGENT FOR BLOCKADE OF T-CELL INHIBITORY MOLECULES

METHODS FOR THE TREATMENT OF OSTEOARTHRITIS

BISPECIFIC SINGLE DOMAIN ANTIBODY TO PD-L1 AND CD47 AND USE THEREOF

METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION

ANTI-CHITINASE-3-LIKE PROTEIN-1 (YKL-40) NEUTRALIZING ANTIBODY AND USES THEREOF

ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA

Antibodies which bind human fibrin or fibrinogen γC domain and methods of use

NEW METHOD TO IMPROVE NK CELLS CYTOTOXICITY

ANTI-5T4 ANTIBODIES AND USES THEREOF

EPCAM TARGETING TRISPECIFIC PROTEIN FOR TREATMENT OF CANCER

Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias

CRTAM ANTIBODIES AND METHODS OF TREATING CANCER

OFATUMUMAB FOR TREATING MULTIPLE SCLEROSIS IN ASIAN PATIENTS

ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF

COMBINATION THERAPIES WITH ANTI CD40 ANTIBODIES

SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES

Method for Treating Chronic Obstructive Pulmonary Disease With an ST2 Antagonist

CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES

mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS

ANTI-MET ANTIBODIES AND USES THEREOF

ANTI-DOMAIN IV EGFR ANTIBODIES AND USES THEREOF

ANTI-NKG2D ANTIBODIES AND USES THEREOF

SINGLE DOMAIN ANTIBODY AGAINST PD-L1 AND USE THEREOF

PANCREAS TARGETED THERAPEUTICS AND USES THEREOF

Agents for Treatment of Claudin Expressing Cancer Diseases

ANTI-ILT4 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS

VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF

USES OF IL-13 ANTAGONISTS FOR TREATING ATOPIC DERMATITIS

ANTI-UNC5C ANTIBODIES

MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF

VEGFA-BINDING MOLECULES

ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING A THROMBOTIC DISEASE OF THE RETINA

ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF

NANOBODY FOR PREVENTING OR TREATING SCHIZOPHRENIA

Methods for Monoclonal Antibody Generation

Antibody specific to spike protein of SARS-CoV-2 and uses thereof

CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN THERAPY

PEPTIDES AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICA

DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES

TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA

Improved immunoglobulin II

HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB

ENGINEERED NK CELLS AND USES THEREOF

CD8(+) Stem-Like Chronic Memory Cell Based Therapies and Compositions Related Thereto

Methods of Producing Improved Immune Cell Populations

ANTI-PSMA ANTIBODIES AND CAR-T STRUCTURES

LOW INTENSITY ULTRASOUND COMBINATION CANCER THERAPIES

IMMUNE CHECKPOINT INHIBITOR AND HDAC INHIBITOR COMBINATION THERAPY STRATEGY

DIAGNOSTIC AND TREATMENT OF CANCER USING C-MET INHIBITOR

MOLECULES WITH ENGINEERED ANTIBODY CONSTANT REGION VARIANTS

METHODS FOR THE ADMINISTRATION OF ADAMTS BINDING IMMUNOGLOBULINS

METHODS FOR TREATING AND/OR PREVENTING IDIOPATHIC PNEUMONIA SYNDROME (IPS) AND/OR CAPILLARY LEAK SYNDROME (CLS) AND/OR ENGRAFTMENT SYNDROME (ES) AND/OR FLUID OVERLOAD (FO) ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANT

PLASMA KALLIKREIN ANTIBODIES AND USES THEREOF

ANTI-CD47 AGENT-BASED TREATMENT OF CD20-POSITIVE CANCER

THERAPEUTIC ANTIBODIES

USE OF CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS TO TREAT CANCER

ANTI-CD73 ANTIBODY AND USE THEREOF

METHODS FOR TREATING NEPHROTIC SYNDROME

ANTI-CD40 ANTIBODY AND USE THEREOF

FAP BINDING DOMAINS AND BISPECIFIC BINDING MOIETIES THAT BIND FAP AND TGF-ßRII

USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY IN TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER

METHODS FOR TREATING VASCULAR INFLAMMATION, ATHEROSCLEROSIS AND RELATED DISORDERS

DLL3 TARGETING TRISPECIFIC PROTEINS AND METHODS OF USE

FC-REGION VARIANTS WITH MODIFIED FCRN-BINDING PROPERTIES

TGF-Beta 1 INHIBITORS FOR PREVENTING AND TREATING SARS-COV-2

NUCLEOCAPSID-SPECIFIC ANTIBODIES AND METHODS FOR THE TREATMENT AND PREVENTION OF SARS-COV-2 INFECTION THEREWITH

ENGINEERING BIOLOGICS TO HPV ONCOPROTEINS

METHODS OF SCREENING AND EXPRESSION OF DISULFIDE-BONDED BINDING POLYPEPTIDES

APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF

Fusion proteins for the treatment of cardiometabolic diseases

MULTI SPECIFIC MOLECULES

ENHANCEMENT OF TREATMENT WITH IMMUNOTHERAPEUTIC AGENTS

NON-VIRAL DNA VECTORS EXPRESSING ANTI-CORONAVIRUS ANTIBODIES AND USES THEREOF

CHIMERIC ANTIGEN RECEPTORS TO SIALYL-TN GLYCAN ANTIGEN

Universal vaccine platform

CLAUDIN 18.2 TARGETING CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS AND USES THEREOF

INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY

COMPOSITIONS AND METHODS FOR DETECTING AND REGULATING FIBRONECTIN-INTEGRIN INTERACTIONS AND SIGNALING

COMPOSITIONS AND METHODS FOR DETECTING AND TREATING PATHOLOGICAL FIBROBLAST CELLS

HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF

ANTI-MASP2 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF

ANTI-GPC3 AND ANTI-CD137 MULTISPECIFIC ANTIBODIES AND METHODS OF USE

ANTI-CD20 ANTIBODY COMPOSITIONS

TUMOR ANTIGEN-DEPENDENT CD40 AGONISTS ANTIBODIES

Anti-CLDN4/anti-CD137 bispecific antibody

ANTI-CD137 ANTIBODIES AND METHODS OF USE

BINDING MOLECULES THAT BIND CD137 AND PD-L1

Compositions and methods related to IL27 receptor binding

HETEROMERIC AGONISTIC ANTIBODIES TO IL-18 RECEPTOR

NOVEL ANTI-HVEGFR2 ANTIBODIES

FUSION PROTEINS WITH SPECIFITY FOR TYPE II COLLAGEN AND VEGF-A FOR THE TREATMENT OF EYE DISEASES

POLYPEPTIDES WITH ALTERED BINDING TO NEONATAL FC RECEPTOR (FCRN) AND METHODS OF USE

ANTI-HUMAN PD-L1 ANTIBODIES AND THEIR USES

NEW STABLE ANTI-VISTA ANTIBODY

SINGLE DOMAIN PD-L1 ANTIBODIES

CD8 BINDING POLYPEPTIDE AND USE THEREOF

THERAPEUTIC ANTIBODIES